LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,415,489
تعداد دریافت فایل اصل مقاله11,291,282
Khaja Pasha, Roya Payam, Shokri, Fazel. (1387). Immunologic Basis and Immunoprophy-laxis of RhD Induced Hemolytic Disease of the Newborn (HDN). سامانه مدیریت نشریات علمی, 5(4), 189-200.
Roya Payam Khaja Pasha; Fazel Shokri. "Immunologic Basis and Immunoprophy-laxis of RhD Induced Hemolytic Disease of the Newborn (HDN)". سامانه مدیریت نشریات علمی, 5, 4, 1387, 189-200.
Khaja Pasha, Roya Payam, Shokri, Fazel. (1387). 'Immunologic Basis and Immunoprophy-laxis of RhD Induced Hemolytic Disease of the Newborn (HDN)', سامانه مدیریت نشریات علمی, 5(4), pp. 189-200.
Khaja Pasha, Roya Payam, Shokri, Fazel. Immunologic Basis and Immunoprophy-laxis of RhD Induced Hemolytic Disease of the Newborn (HDN). سامانه مدیریت نشریات علمی, 1387; 5(4): 189-200.

Immunologic Basis and Immunoprophy-laxis of RhD Induced Hemolytic Disease of the Newborn (HDN)

Iranian Journal of Immunology
مقاله 1، دوره 5، شماره 4، اسفند 2008، صفحه 189-200    اصل مقاله (181.81 K)
نوع مقاله: Review Article
نویسندگان
Roya Payam Khaja Pasha1؛ Fazel Shokri* 2، 3
1StemCore Laboratories, Sprott Centre for Stem Cell Research, Ottawa Health Research Institute, Ottawa, Canada
2Department of Immunology, School of Public Health, Tehran University of Medical Sciences
3National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran
چکیده
RhD antigen is the most immunogenic and clinically significant antigen of red blood cells after ABO system. It has historically been associated with hemolytic disease of the newborn (HDN) which is now routinely prevented by the administration of polyclonal anti-D immunoglobulin. This management of HDN has proven to be one of the most successful cases of prophylactic treatment based on antibody mediated immune sup-pression (AMIS). Despite the increasing efficiency of treatment, the mechanism of ac-tion of anti-D is not completely defined. There is a widespread interest in obtaining a reliable therapeutic monoclonal anti-D, due to difficulty of maintaining a pool of high titer volunteer donors for plasma collection and also increasing demand for antenatal prophylaxis and safety issues with plasma derived products. Candidate monoclonal anti-D preparations should demonstrate appropriate functionality in both in vitro and in vivo assays comparable to polyclonal anti-D immunoglobulin. These criteria are reviewed in addition to the factors regulating development of D specific immune response in D negative individuals and its suppression in HDN prophylaxis.
کلیدواژه‌ها
Anti-D immunoglobulin؛ D antigen؛ Hemolytic Disease of the Newborn (HDN)؛ Monoclonal anti-D؛ Rh Blood Group System
آمار
تعداد مشاهده مقاله: 1,494
تعداد دریافت فایل اصل مقاله: 1,161


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب